Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-07-29 DOI:10.1038/s41571-024-00931-w

Diana Romero

引用次数: 0

查看原文本刊更多论文

安罗替尼联合苯美司托巴特和化疗对ES-SCLC有效

广泛期小细胞肺癌（ES-SCLC）患者通常接受铂类化疗加免疫检查点抑制剂（ICI）作为一线疗法，但疾病复发是一个令人担忧的问题。现在，来自III期ETER701试验的数据表明，抗血管生成药物安罗替尼加上抗PD-L1抗体本迈斯托巴特和化疗的联合疗法在这种情况下具有良好的疗效。患者被随机分配接受安罗替尼+苯美司巴特和化疗（三联方案；n = 246）、安罗替尼+安慰剂和化疗（双联方案；n = 245）或双安慰剂+化疗（试验设计时中国的标准治疗方案）（n = 247）。无进展生存期（PFS）和总生存期（OS）为共同主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.